Moderna Inc [MRNA] stock is trading at $41.41, down -2.31%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRNA shares have gain 22.66% over the last week, with a monthly amount glided 5.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on December 18, 2024, when Argus downgraded its rating to a Hold. On November 19, 2024, Berenberg initiated with a Hold rating and assigned a price target of $42 on the stock. HSBC Securities upgraded its rating to a Buy but stick to its price target of $58 on November 18, 2024. Wolfe Research initiated its recommendation with a Underperform and recommended $40 as its price target on November 15, 2024. Bernstein started tracking with a Mkt Perform rating for this stock on October 17, 2024, and assigned it a price target of $55. In a note dated September 13, 2024, Oppenheimer downgraded an Perform rating on this stock.
Moderna Inc [MRNA] stock has fluctuated between $31.94 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $104.9 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $41.41 at the most recent close of the market. An investor can expect a potential return of 153.32% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Moderna Inc [NASDAQ:MRNA] reported sales of 5.07B for the trailing twelve months, which represents a growth of 1.69%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.46%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.18 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.66 points at the first support level, and at 37.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.28, and for the 2nd resistance point, it is at 47.15.
Ratios To Look Out For
For context, Moderna Inc’s Current Ratio is 4.39. On the other hand, the Quick Ratio is 4.20, and the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 3.14, the price to book ratio is 1.34.
Transactions by insiders
Recent insider trading involved Klinger Shannon Thyme, Chief Legal Officer, that happened on Dec 09 ’24 when 529.0 shares were sold. Officer, Klinger Shannon Thyme completed a deal on Dec 09 ’24 to buy 529.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 112.0 shares on Dec 03 ’24.
